Pancreatic CancerPREDIPSNCT02756468
Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS Study
An observational study of Pancreatic Cancer, run by University of Roma La Sapienza at 1 site in Italy.
Trial summary
Background. Pancreatic cancer surgery is associated with very high risk of postoperative morbidity and mortality. Anastomotic leak (AL) is one of the worst complications associated with relevant short and long-term sequelae. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Pancreatic Cancer
- What is being tested?
- pts operated for pancreatic cancer
- How many people
- 100 participants
- Where
- 1 siteItaly
- Study dates
- Jan 2015to Dec 2016
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: all pts undergoing pacreatic resections for cancer
Who may be able to join
- patients undergoing all different kinds of pancreatic surgery
- in elective setting
- for cancer
- with a pancreatic anastomosis performed.
Who cannot join
- age < 18 years
- pregnant women
- patients undergoing pancreatic surgery for benign disease, other kinds of pancreatic surgery without an anastomosis being performed
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
Sant'Andrea University Hospital
Rome, 00189
Valentina Giaccaglia, MD, 00393397882429, v.giaccaglia@gmail.com
Valentina Giaccaglia, MD
About this study
Background. Pancreatic cancer surgery is associated with very high risk of postoperative morbidity and mortality. Anastomotic leak (AL) is one of the worst complications associated with relevant short and long-term sequelae. Procalcitonin (PCT) is a biomarker used to monitor bacterial infections and guide antibiotic therapy and has been shown to have better predictive value of AL after colorectal surgery than C-reactive protein (CRP) and white blood cell count (WBC).
Purpose. The investigators designed a monocentric pilot study to test if PCT might be a sensitive and reliable marker of AL after pancreatic surgery
- Conditions
- Pancreatic Cancer
- Being tested
- pts operated for pancreatic cancer
- Keywords
- pancreatic cancer, procalcitonin
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
pts operated for pancreatic cancerOther
measuring CRP and PCT in 3rd and 5th POD after pancreatic cancer resection
| Study group | Role | What they receive |
|---|---|---|
| pts operated for pancreatic cancer | all pts operated of pancreatic resection for cancer in the involved units Receives: Other: pts operated for pancreatic cancer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensitivity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery
Sensitivity: % of patients corrected identified by the biomarkers having AL; PCT: procalcitonin, CRP: C-reactive protein, AL: anastomic leak
Measured: 2 yrs
Specificity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery
Specificity: % of pts corrected identified by the biomarkers not having AL; PCT: procalcitonin, CRP: C-reactive protein, AL: anastomic leak
Measured: 2 yrs
Secondary outcomes (2)
PCT and CRP cuts-off in 3rd POD with a good NPV for AL
PCT: procalcitonin, CRP: C-reactive protein, NPV: negative predictive value
Measured: 2 yrs
PCT and CRP cuts-off in 5th POD with a good NPV for AL
PCT: procalcitonin, CRP: C-reactive protein, NPV: negative predictive value
Measured: 2 yrs
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2016 (estimated)
- Study startJan 2015
- Primary completionJun 2016 (estimated)
- Study completionDec 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- More trials run by University of Roma La SapienzaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- University of Roma La Sapienza
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Valentina Giaccaglia, University of Roma La Sapienza
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02756468
- Sponsor's protocol ID
- PREDIPS
- Acronym
- PREDIPS
- Status last verified
- Apr 2016
- First submitted
- 18 Apr 2016
- Last updated
- 29 Apr 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS Study
- ClinicalTrials.gov ID
- NCT02756468
- Acronym / sponsor ID
- PREDIPS / PREDIPS
- Conditions
- Pancreatic Cancer
- Keywords
- pancreatic cancer, procalcitonin
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University of Roma La SapienzaUniversity, hospital or other
- Study start
- Jan 2015
- Primary completion
- Jun 2016 (estimated)
- Study completion
- Dec 2016 (estimated)
- First posted
- 29 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background. Pancreatic cancer surgery is associated with very high risk of postoperative morbidity and mortality. Anastomotic leak (AL) is one of the worst complications associated with relevant short and long-term sequelae. Procalcitonin (PCT) is a biomarker used to monitor bacterial infections and guide antibiotic therapy and has been shown to have better predictive value of AL after colorectal surgery than C-reactive protein (CRP) and white blood cell count (WBC).
Purpose. The investigators designed a monocentric pilot study to test if PCT might be a sensitive and reliable marker of AL after pancreatic surgery
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 2 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| pts operated for pancreatic cancer | – | Other: pts operated for pancreatic cancerall pts operated of pancreatic resection for cancer in the involved units |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- all pts undergoing pacreatic resections for cancer
Key inclusion criteria (4 listed)
- patients undergoing all different kinds of pancreatic surgery
- in elective setting
- for cancer
- with a pancreatic anastomosis performed.
Key exclusion criteria (3 listed)
- age < 18 years
- pregnant women
- patients undergoing pancreatic surgery for benign disease, other kinds of pancreatic surgery without an anastomosis being performed
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| pts operated for pancreatic cancermeasuring CRP and PCT in 3rd and 5th POD after pancreatic cancer resection | Other | pts operated for pancreatic cancer |
Primary outcome
Sensitivity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery
Time frame: 2 yrs
Sensitivity: % of patients corrected identified by the biomarkers having AL; PCT: procalcitonin, CRP: C-reactive protein, AL: anastomic leak
Specificity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery
Time frame: 2 yrs
Specificity: % of pts corrected identified by the biomarkers not having AL; PCT: procalcitonin, CRP: C-reactive protein, AL: anastomic leak
2 secondary outcomes
PCT and CRP cuts-off in 3rd POD with a good NPV for AL
Time frame: 2 yrs
PCT and CRP cuts-off in 5th POD with a good NPV for AL
Time frame: 2 yrs
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2016.
- Individual participant dataSharing planned: No
Related trials for Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Cancer, run by University of Roma La Sapienza at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 29 Apr 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Valentina Giaccaglia, MD (+393397882429, v.giaccaglia@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensitivity of PCT and CRP for anastomotic leak (AL) after pancreatic surgery (time frame: 2 yrs). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2016.